RxDoctor Payments Data

Joseph Reyes, DO

Pain Medicine · Greenfield, WINPI 1528054947

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,683 of the $9,011 with a category attached, or 63.1%. 37 manufacturers reported payments, led by International Rehabilitative Sciences, Inc at 37.2% of the total. 2025 is the largest year on record at $4,571, 5.8 times the $785 reported in 2019.

$9,011in general payments, 2019–2025

Across 192 payments — averaging $46.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • International Rehabilitative Sciences, Inc$3K
  • Boston Scientific$1K
  • Abbott$619
  • Medtronic$619
  • Nevro Corp.$546
  • Collegium Pharmaceutical, Inc.$536
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,68363%
  • Other$3,32837%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,011 in reported general payments places this provider in the 75th percentile of 82 pain medicine providers in Wisconsin.

See all pain medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$80,679
Medicare patients
154
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl36$21,755
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen141$5,007
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen144$4,528
Lidocaine18$2,979
Buprenorphine17$2,961
Morphine Sulfate ErMorphine Sulfate72$2,311
Oxycodone Hcl72$952
Acetaminophen-CodeineAcetaminophen With Codeine21$895
Pregabalin54$893
Gabapentin70$817
Cyclobenzaprine Hcl33$805
Morphine Sulfate19$739
Tizanidine Hcl39$576
Tramadol Hcl49$337
Baclofen11$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$536$21,75536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 82 pain medicine providers in Wisconsin.

Other pain medicine in Greenfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →